publication date: Oct. 1, 2015

NCI CTEP-Approved Trials For the Month of September


The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.


Phase I

9834: A Phase I Study of Methoxyamine Combined with Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer. Case Western Reserve University; Biswas, Tithi. (216) 286-6740


9874: A Phase I Trial of AT13387 in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin. University Health Network Princess Margaret Cancer Center LAO; Hope, Andrew J. (416) 946-2124


ADVL1416: A Phase 1 Study of Ramucirumab, a Human, Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors. COG Phase 1 Consortium; Pradhan, Kamnesh. (317) 944-8784


Phase I/II

9837: Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed. City of Hope Comprehensive Cancer Center LAO; Koczywas, Marianna. (626) 256-4673


Phase II

A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive … Continue reading CCL Sept – NCI CTEP-Approved Trials For the Month of September

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.